Li Juan YeYunnan Cancer Hospital, China
Title: SRSF1 induces glioma progression and has a potential diagnostic application in grading primary glioma
Glioma is the most common intracranial tumor of the central nervous system in adults. Our results revealed that SRSF1 expression was significantly associated with the grading and the histopathological subtype of glioma. As determined using a ROC curve analysis, the specificity of SRSF1 for glioblastoma (GBM) and WHO grade 3 astrocytoma was 40 and 48%, respectively, whereas the sensitivity was 100 and 85%. By contrast, pilocytic astrocytoma tumors exhibited negative immunoexpression of SRSF1. Additionally, Kaplan-Meier survival analysis indicated that high SRSF1 expression predicted a worse prognosis for patients with glioma in both the CGGA and clinical cohorts. In vitro, the results demonstrated that SRSF1 promoted the proliferation, invasion and migration of U87MG and U251 cells. These data suggested that immunohistochemical analysis of SRSF1 expression is highly sensitive and specific in the diagnosis of GBM and WHO grade 3 astrocytoma, and may have an important role in glioma grading. Furthermore, the lack of SRSF1 is a potential diagnostic biomarker for pilocytic astrocytoma. However, neither in oligodendroglioma and astrocytoma, nor in GBM was an association detected between SRSF1 expression and IDH1 mutations or 1p/19q co ? deletion. These findings indicated that SRSF1 may serve as a prognostic factor in glioma cases and could have an active role in promoting glioma progression.
Lijuan Ye completed his PhD at the age of 38 years from Kunming Medical University, China. She is a pathologist from Yunnan Cancer Hospital, China. She is skilled in tumor pathological diagnosis. She has many publications.